Research programme: retinal gene therapeutics - Orbit Biomedical
Latest Information Update: 28 Jul 2022
Price :
$50 *
At a glance
- Originator Orbit Biomedical
- Developer Janssen Biotech
- Class Cell therapies; Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinal disorders